Clinical Trials in Surgical Oncology

Published:November 03, 2022DOI:
      In this issue of Surgical Oncology Clinics of North America, we have asked some of the leading clinical researchers in the field of Surgical Oncology to discuss the importance and impact of conducting clinical trials. This issue can be used as a primer for trainees, as well as established surgeons, on how to develop clinical studies both at an institutional level and within the framework of the NCTN cooperative group structure. We have also summarized “The State of Science” with an update on the most surgically relevant clinical trials broken down by disease-based articles. Last, we also focus an article on the need to improve diversity and equity in conducting clinical trials. If results from these studies are to be applicable to broad populations, the trial participants need to reflect, as much as possible, the population of patients with the disease. We know that differences in response to therapy can exist among different ethnic and racial populations based on nuclear polymorphisms, pharmacogenomics, and other factors. Thus, an emphasis on improving diversity and equity within clinical trial enrollment, as well as interpretation of results, will be necessary for future studies. In closing, we would like to dedicate this issue of Surgical Oncology Clinics of North America to all the patients with cancer and their families that have enrolled and participated in clinical trials with the goal of improving cancer care for future patients.